BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1550 related articles for article (PubMed ID: 25062733)

  • 1. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
    van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
    Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
    Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
    Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels.
    Shin A; Shin B; Shin JW; Kim KH; Atwal RS; Hope JM; Gillis T; Leszyk JD; Shaffer SA; Lee R; Kwak S; MacDonald ME; Gusella JF; Seong IS; Lee JM
    Hum Mol Genet; 2017 Apr; 26(7):1258-1267. PubMed ID: 28165127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making (anti-) sense out of huntingtin levels in Huntington disease.
    Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM
    Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There Convincing Evidence that Intermediate Repeats in the HTT Gene Cause Huntington's Disease?
    Oosterloo M; Van Belzen MJ; Bijlsma EK; Roos RA
    J Huntingtons Dis; 2015; 4(2):141-8. PubMed ID: 26397895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease.
    Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J
    Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
    Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
    PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models.
    Joachimiak P; Ciesiołka A; Kozłowska E; Świtoński PM; Figura G; Ciołak A; Adamek G; Surdyka M; Kalinowska-Pośka Ż; Figiel M; Caron NS; Hayden MR; Fiszer A
    BMC Biol; 2023 Feb; 21(1):17. PubMed ID: 36726088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
    Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
    J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
    Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
    Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a predisposing background for CAG expansion leading to HTT mutation in a Chinese population.
    Ma M; Yang Y; Shang H; Su D; Zhang H; Ma Y; Liu Y; Tao D; Zhang S
    J Neurol Sci; 2010 Nov; 298(1-2):57-60. PubMed ID: 20864123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin gene CAG repeat size affects autism risk: Family-based and case-control association study.
    Piras IS; Picinelli C; Iennaco R; Baccarin M; Castronovo P; Tomaiuolo P; Cucinotta F; Ricciardello A; Turriziani L; Nanetti L; Mariotti C; Gellera C; Lintas C; Sacco R; Zuccato C; Cattaneo E; Persico AM
    Am J Med Genet B Neuropsychiatr Genet; 2020 Sep; 183(6):341-351. PubMed ID: 32652810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haplotype analysis of the CAG and CCG repeats in 21 Brazilian families with Huntington's disease.
    Agostinho Lde A; Rocha CF; Medina-Acosta E; Barboza HN; da Silva AF; Pereira SP; da Silva Idos S; Paradela ER; Figueiredo AL; Nogueira Ede M; Alvarenga RM; Hernan Cabello P; dos Santos SR; Paiva CL
    J Hum Genet; 2012 Dec; 57(12):796-803. PubMed ID: 23051704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.